Searchable abstracts of presentations at key conferences in endocrinology

ea0081p184 | Reproductive and Developmental Endocrinology | ECE2022

Effects of testosterone therapy on bone turnover markers and bone mineral density in obese males with type 2 diabetes and functional hypogonadism

Groti Antonic Kristina

Aims: Both functional hypogonadism (FH) and type 2 diabetes (T2D) negatively affect bone mineral density (BMD). We aimed to evaluate changes on bone turnover markers (BTMs) and BMD in obese males with FH and T2D due to testosterone therapy (TTh).Research Design and Methods: 55 obese males with FH and T2D participated in a two-year (first year double-blind, placebo-controlled study, second year follow-up) clinical trial. Participants were randomized into ...

ea0090p724 | Reproductive and Developmental Endocrinology | ECE2023

Effects of testosterone therapy on erythrocytosis and prostate adverse events in obese males with functional hypogonadism and type 2 diabetes

Groti Antonic Kristina

Aims: Testosterone therapy (TTh) has been postulated to increase the risk of prostate adverse events (PAEs) and erythrocytosis, risk further exacerbated in high-risk obese patients with type 2 diabetes (T2D) and functional hypogonadism (FH). We investigated safety aspects of TTh in obese males with FH and T2D by observing the incidence of PAEs and erythrocytosis and determining when statistically significant difference from the baseline manifests in hematocrit (Hct) and prosta...

ea0090p741 | Reproductive and Developmental Endocrinology | ECE2023

Functional hypogonadism and prevalence of decreased total testosterone level in type 2 diabetic male patients

Groti Antonic Kristina

Functional hypogonadism and prevalence of decreased total testosterone level in type 2 diabetic male patientsBackground: Approximately 50 % of older males with obesity and type 2 diabetes, exhibit low total testosterone levels, many also signs of hypogonadism. Functional hypogonadism negatively affects glycemic control, exacerbates early cardio-vascular complications, causes lower bone mineral density, erectile dysfunction, reduces lean body mass, and ac...

ea0063gp42 | Metabolic Syndrome and Hypoglycaemia | ECE2019

Magnitude of effects of testosterone replacement therapy on testosterone normalization, parameters of metabolic syndrome and vascular function and morphology in obese hypogonadal patients with type 2 diabetes – the SETH2 study

Groti Antonic Kristina

Background: The association between testosterone deficiency, metabolic syndrome (MetS) and type 2 diabetes (T2DM) is well established. Male hypogonadism is related to an increase in glycometabolic and cardiometabolic complications.Objective: To evaluate magnitude of effects of testosterone replacement therapy (TRT) on testosterone normalization, parameters of the MetS and vascular function and morphology in obese hypogonadal male patients with T2DM.<...

ea0043oc5 | Cardiovascular Outcome Studies | WCTD2016

Diabetes and blood pressure rhythm abnormalities

Klaric Dragan , Artukovic Kristina

Background: The absence of blood pressure dip during sleep is a common disorder in patients on dialysis, especially those with diabetes. Non-dipping is clinically significant as a predictor of cardiovascular events and an overview of the situation is possible only during ambulatory blood pressure monitoring (AMP), especially during sleep.Objective: Inversion of nighttime blood pressure is an indication of worse outcomes.Methods: Du...

ea0073pep7.1 | Presented ePosters 7: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Effects of testosterone therapy on morphology and grade of NAFLD in obese men with functional hypogonadism and type 2 diabetes

Antonic Kristina Groti

AimsNon-alcoholic fatty liver disease (NAFLD) is emerging as a public health issue worldwide, is highly prevalent in patients with type 2 diabetes (T2D), and is linked to obesity, insulin resistance and atherogenic dyslipidemia. We aimed to evaluate effects of testosterone therapy (TTh) on morphology and grade of NAFLD in obese men with functional hypogonadism (FH) and T2D.Research design and methods55 obese ...

ea0063p565 | Diabetes, Obesity and Metabolism 2 | ECE2019

Giant prolactinoma associated with alopecia universalis (AU): a case report

Liesionyte Kristina , Pauliukiene Renata , Knispelis Robertas

Introduction: Giant prolactinomas are rare tumours, they represent range from 0.5 to 4.0% of all pituitary tumours. We are presenting a patient with giant prolactinoma without visual field defects and any obvious clinical symptoms related to hyperprolactinemia and probably associated with alopecia universalis.Case: 32 years old man has visited outpatient department of our hospital, complaining of severe headache for the last three years. He underwent bra...

ea0049ep156 | Endocrine tumours and neoplasia | ECE2017

Imaging follow-up of non-functioning adrenal masses at Vilnius University Hospital Santariskiu Klinikos: 2010–2016

Svaikeviciene Kristina , Girdziute Milda , Visockiene Zydrune

Background: Current guidelines suggest against further imaging follow-up (FU) of patients with non-functioning adrenal masses with clear benign features on imaging studies.Aim: To analyse the data of patients with non-functioning adrenal masses who had FU at Vilnius University Hospital Santariskiu Klinikos (VUHSK) from 2010 to 2016.Methods: Cases coded as D35.0; D44.1; C74.1; C74.9; E26.0; E27,8; E24,8 according to ICD-10 classific...

ea0073aep598 | Reproductive and Developmental Endocrinology | ECE2021

Successful twin delivery in a patient with partial 46, XY gonadal dysgenesis

Semeniene Kristina , Navardauskaite Ruta , Tomas Preiksa Romualdas

IntroductionPartial gonadal dysgenesis (PGD) is one of the rare 46, XY disorders of sex development (DSD), associated with variable degrees of impaired testicular development and function. Phenotypic appearance is related to the level of functional testicular hormones. Usually PGD is diagnosed in infancy because of significant genital anomaly at birth, however, spontaneous puberty is seen in up to 57% of all 46, XY PGD cases. Bilateral gonadectomy is per...

ea0081p651 | Environmental Endocrinology | ECE2022

Di-(2-ethylhexyl) phthalate decreases forskolin-stimulated progesterone synthesis in human granulosa cells

Samardzija Nenadov Dragana , Tesic Biljana , Andric Nebojsa , Pogrmic-Majkic Kristina

Di-(2-ethylhexyl) phthalate (DEHP) is an endocrine disruptor that belongs to the group of phthalates. Human exposure to DEHP is ubiquitous, considering its use in plastics and other common consumer products. In vivo and in vitro studies demonstrate its harmful effects on female reproductive system. The aim of this study was to investigate the effects of short term exposure to DEHP on progesterone synthesis in human granulosa cells. The human nonluteinized gra...